Monday, 18 August 2014
Drug discovery is well-known as the process by
which drugs are revealed or designed. A few times back most drugs came to know
either by identifying the active ingredient from traditional remedies or either
by chance discoveries.
A latest approach explains how disorders,
diseases, illness and infections are controlled by ease at the molecular and
physiological level and to target specific entities based on this apprehensive.
Without being affected by the advances in the technology and understanding of
biological systems, drug discovery is still though a time consuming, costly,
strenuous, and inefficient procedure with low rate of new disease healing
discoveries.
In 2010, the complete research and development
cost of each new molecular entity (NME) was approximately US$1.8 billion. Drug Discovery is finalized by pharmaceutical
companies, with highly research assistance from universities.
The conclusive outcome of drug discovery is a patent on the potential drug. The drug requires very expensive Phases clinical
trials, and most of them are unsuccessful. Companies at small scale have a
critical role, often then selling the rights to large scale
companies that have the resources to run the clinical trials.
Discovering drugs that may be a commercial
success or a public health success involves a complex interaction between
investors; industry, patent laws, regulatory exclusivity, marketing and the
need to balance secrecy with communication.
For a complete list, click on Bentham Science Publishers’ Journals Impacting Science
